Iovance weekly recap highlights melanoma TIL and 2026 guidance review

TradingView News recap cites reports of durable melanoma responses for Iovance’s TIL therapy, and says the company is reassessing full-year 2026 revenue guidance ahead of Q2. The recap also notes investors remain focused on near-term catalysts ahead of the Q4 update, with durable NSCLC data referenced for Lifileucel.